Three-year outcomes of the postapproval study of the AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation Trial.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
08 2022
Historique:
received: 15 02 2019
revised: 08 09 2020
accepted: 15 09 2020
pubmed: 2 11 2020
medline: 20 7 2022
entrez: 1 11 2020
Statut: ppublish

Résumé

The Cox Maze IV operation is commonly performed concomitant with other cardiac operations and effectively reduces the burden of atrial fibrillation. Prospective randomized trials have reported outcomes early and at 12 months, but only single-center late durability results are available. As part of the postapproval process for a bipolar radiofrequency ablation system, we sought to determine early and midterm outcomes of patients undergoing the Cox Maze IV operation. A prospective, multicenter, single-arm study of 363 patients (mean age, 70 years, 82% valve surgery) with nonparoxysmal atrial fibrillation (mean duration, 60 months, 94% Congestive heart failure, Hypertension, Age ≥ 75, Diabetes, Stroke, VAScular disease, Age 65-74, Sex category ≥2) undergoing concomitant Maze IV atrial fibrillation ablation at 40 sites with 70 surgeons was performed between June 2010 and October 2014. Compliance with the study lesion set was 94.5%, and 99% had left atrial appendage closure. Freedom from atrial fibrillation was determined by extended monitoring, with a 48-hour Holter monitor minimum. There were no device-related complications. Freedom from atrial fibrillation off antiarrhythmic medications at 1, 2, and 3 years was 66%, 65%, and 64%, respectively, and including those using antiarrhythmics was 80%, 78%, and 76%, respectively. Warfarin was used in 49%, 44%, and 40%, respectively. In patients with nonparoxysmal atrial fibrillation, compliance with the protocol was high, and freedom from atrial fibrillation off antiarrhythmics was high and sustained to 3 years. The safety and effectiveness of the system and Cox Maze IV procedure support the Class I guideline recommendation for concomitant atrial fibrillation ablation in patients undergoing cardiac surgery.

Identifiants

pubmed: 33129501
pii: S0022-5223(20)32702-1
doi: 10.1016/j.jtcvs.2020.09.099
pii:
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

519-527.e4

Informations de copyright

Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Patrick M McCarthy (PM)

Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine, Bluhm Cardiovascular Institute, Chicago, Ill. Electronic address: pmccart@nm.org.

Marc Gerdisch (M)

Department of Cardiovascular and Thoracic Surgery, Franciscan St Francis Heart Center, Indianapolis, Ind.

Jonathan Philpott (J)

Sentara Heart Hospital, Norfolk, Va.

Glenn R Barnhart (GR)

Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, Wash.

Albert L Waldo (AL)

Division of Cardiovascular Medicine, Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

Richard Shemin (R)

Division of Cardiac Surgery, Department of Surgery, School of Medicine at UCLA, Los Angeles, Calif.

Adin-Cristian Andrei (AC)

Department of Preventive Medicine, Northwestern University, Chicago, Ill.

Sydney Gaynor (S)

AtriCure, Inc, Mason, Ohio.

Nfii Ndikintum (N)

AtriCure, Inc, Mason, Ohio.

Hugh Calkins (H)

Division of Cardiology, Johns Hopkins Hospital, Baltimore, Md.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH